Announcements Trials
Browse Landscape

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Sarcoma 1Genitourinary 1Dermatologic 1

Conditions

Melanoma 2Urinary Bladder Neoplasms 1Testicular Neoplasms 1Sarcoma 1Prostatic Neoplasms 1

Interventions

Cyclophosphamide 16pembrolizumab 14Radiosurgery 7Nivolumab 5Celecoxib 5poly ICLC 4Radiation 4Injections 4Radiotherapy 3Melphalan 3Ipilimumab 3Filgrastim 3Etoposide 3Docetaxel 3Cryosurgery 3Blood Specimen Collection 3Biopsy 3130-nm albumin-bound paclitaxel 3trastuzumab deruxtecan 2tislelizumab 2talimogene laherparepvec 2spartalizumab 2fludarabine phosphate 2fludarabine 2durvalumab 2cemiplimab 2atezolizumab 2aldesleukin 2Transurethral Resection of Prostate 2Therapeutics 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sarcoma × Histocompatibility Testing × Dermatologic × Clear all
NCT05819827 2025-04-27

Associations Between Chemotherapy-Induced Nausea in Patients With Genitourinary, Sarcoma or Melanoma Cancers and Changes in Gut Microbiome: Potential for Precision Therapeutics

Mayo Clinic

Terminated
13 enrolled
DermatologicGenitourinarySarcoma

Urinary Bladder Neoplasms, Melanoma, Prostatic Neoplasms, Sarcoma, Testicular Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡